Department of Urology, New York University Medical Center, New York, NY.
Department of Population Health, New York University Medical Center, New York, NY.
JCO Oncol Pract. 2023 May;19(5):e763-e772. doi: 10.1200/OP.22.00147. Epub 2023 Jan 19.
Black men have a higher risk of prostate cancer diagnosis and mortality but are less likely to receive definitive treatment. The impact of structural aspects on treatment is unknown but may lead to actionable insights to mitigate disparities. We sought to examine the associations between urology practice organization and racial composition and treatment patterns for Medicare beneficiaries with incident prostate cancer.
Using a 20% sample of national Medicare data, we identified beneficiaries diagnosed with prostate cancer between January 2010 and December 2015 and followed them through 2016. We linked urologists to their practices with tax identification numbers. We then linked patients to practices on the basis of their primary urologist. We grouped practices into quartiles on the basis of their proportion of Black patients. We used multilevel mixed-effects models to identify treatment associations.
We identified 54,443 patients with incident prostate cancer associated with 4,194 practices. Most patients were White (87%), and 9% were Black. We found wide variation in racial practice composition and practice segregation. Patients in practices with the highest proportion of Black patients had the lowest socioeconomic status (43.1%), highest comorbidity (9.9% with comorbidity score ≥ 3), and earlier age at prostate cancer diagnosis (33.5% age 66-69 years; < .01). Black patients had lower odds of definitive therapy (adjusted odds ratio, 0.87; 95% CI, 0.81 to 0.93) and underwent less treatment than White patients in every practice context. Black patients in practices with higher proportions of Black patients had higher treatment rates than Black patients in practices with lower proportions. Black patients had lower predicted probability of treatment (66%) than White patients (69%; < .05).
Despite Medicare coverage, we found less definitive treatment among Black beneficiaries consistent with ongoing prostate cancer treatment disparities. Our findings are reflective of the adverse effects of practice segregation and structural racism, highlighting the need for multilevel interventions.
黑人男性患前列腺癌的诊断和死亡率更高,但接受确定性治疗的可能性较低。结构方面对治疗的影响尚不清楚,但可能会提供可采取行动的见解,以减轻差异。我们试图研究泌尿外科实践组织和种族构成与接受医疗保险的前列腺癌患者治疗模式之间的关联。
使用全国医疗保险数据的 20%样本,我们确定了 2010 年 1 月至 2015 年 12 月期间被诊断患有前列腺癌的受益人和 2016 年的随访。我们使用税务识别号码将泌尿科医生与其所在的实践联系起来。然后,我们根据主要泌尿科医生将患者与实践联系起来。我们根据黑病人数的比例将实践分为四组。我们使用多水平混合效应模型来确定治疗关联。
我们确定了 54443 名患有前列腺癌的患者,与 4194 家实践相关。大多数患者为白人(87%),9%为黑人。我们发现种族实践构成和实践隔离的差异很大。在黑人患者比例最高的实践中,患者的社会经济地位最低(43.1%的患者患有≥3 种合并症),前列腺癌诊断年龄较早(33.5%的患者年龄为 66-69 岁;<0.01)。黑人患者接受确定性治疗的可能性较低(调整后的优势比,0.87;95%CI,0.81 至 0.93),并且在每种实践环境中都接受的治疗少于白人患者。黑人患者在黑人患者比例较高的实践中接受的治疗率高于黑人患者比例较低的实践。黑人患者的治疗预测概率(66%)低于白人患者(69%;<0.05)。
尽管有医疗保险覆盖,但我们发现黑人受益人的确定性治疗较少,这与前列腺癌治疗的持续差异一致。我们的研究结果反映了实践隔离和结构性种族主义的不利影响,突出了需要采取多层次干预措施。